MedTrace Logo

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

NCT04721223 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-19

No results posted yet for this study

Summary

To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.

Conditions

Interventions

DRUG

JAB-3068

JAB-3068 administrated orally as a tablet.

DRUG

PD1 inhibitor

JS001 administrated as an intravenous(IV) infusion.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Jacobio Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2023-12-29
Completion
2023-12-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721223 on ClinicalTrials.gov